New shot combo targets tough skin cancers when other treatments fail

NCT ID NCT07227870

First seen Nov 15, 2025 · Last updated May 05, 2026 · Updated 18 times

Summary

This study tests a new drug combination (L19IL2 and L19TNF) injected directly into skin tumors for people with advanced basal cell carcinoma that has worsened or cannot be treated with standard therapies. About 92 participants will receive weekly injections for up to two 4-week cycles. The goal is to see if the treatment shrinks tumors and is safe to use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

    Tampa, Florida, 33612, United States

    Contact

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

    Contact

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia, 30322, United States

    Contact

Conditions

Explore the condition pages connected to this study.